Zai Lab Ltd
HKEX:9688
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
13.47
34.55
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Net Margin
Zai Lab Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| CN |
|
Zai Lab Ltd
HKEX:9688
|
15.2B HKD |
-50%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-21 040%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
401B USD |
4%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
176.9B USD |
19%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
155.9B USD |
28%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
115.3B USD |
31%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-392%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.8B USD |
32%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
84.8B AUD |
19%
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
45B EUR |
43%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
53.3B USD |
1%
|
Zai Lab Ltd
Glance View
Zai Lab Ltd. is an innovative player in the biotech and pharmaceutical landscape, emerging from China with ambitions that stretch globally. Founded in 2013, the company has quickly built a robust portfolio, focusing on oncology, autoimmune disorders, infectious diseases, and neuroscience. Zai Lab has established itself with a hybrid business model that intertwines the agility of a biotech startup with the strategic partnerships of a mature pharmaceutical company. This approach has allowed it to localize and expedite the development of cutting-edge therapeutics for the Chinese market while simultaneously building a presence in international markets. What sets Zai Lab apart is its keen ability to in-license late-stage pharmaceutical assets from global partners, significantly cutting down on the time and resources typically required for new drug development. The company generates revenue primarily by commercializing these in-licensed drugs in China and neighboring regions. Zai Lab has also expanded its revenue streams through co-development deals, wherein it collaborates with global pharmaceutical giants. This involves sharing research and development costs, thus reducing upfront investment while simultaneously broadening its pipeline. Furthermore, Zai Lab's financial success is bolstered by its strong market position in several key therapeutic areas, driving growth and reinforcing its status as a bridge between international drug innovation and the Chinese healthcare sector. With a focus on rapid commercialization and strong partnerships, Zai Lab continues to blaze a trail in the biopharma industry, well-suited for navigating both domestic and international markets.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Zai Lab Ltd's most recent financial statements, the company has Net Margin of -49.7%.